产品描述
| 熔点 | 172-183 °C |
| 溶解性 | Soluble in water (very poorly), DMSO (25 mg/ml, with slight warming), ethanol (25 mg/ml, with slight warming), and chloroform. |
| 存贮条件 | 储存温度-20°C |
| 应用 | A piperazinyl quinazoline receptor tyrosine kinase inhibitor |
| 产品介绍 | Tandutinib (MLN518)是一种有效的FLT3拮抗剂，IC50为0.22 μM，同时也抑制PDGFR和c-Kit，对FLT3作用效果比CSF-1R强15到20倍，比FGFR， EGFR和KDR等强100倍以上 |
| 备注 | Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase |
| 生化机理 | Tandutinib is a piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of Flt-3/Flk-2 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis. Tandutinib is an inhibitor of PDGFR-beta. |
| 别名 | 坦度替尼; 4-[6-甲氧基-7-(3-哌啶-1-基丙氧基)喹唑啉-4-基]-N-(4-异丙基氧苯基)哌嗪-1-甲酰胺;MLN518; CT53518; MLN 518; CT 53518; MLN-518; CT-53518;4-[6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide; (4-(6-Methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-N-(4-(methylethoxy)phenyl)carboxamide |
